NEW YORK (GenomeWeb News) – SAIC-Frederick will use Silicon Kinetics’ technology platform to study protein interactions in cancer and AIDS and to determine how drugs affect those interactions, Silicon Kinetics said today.
Under the agreement, National Cancer Institute contractor SAIC-Frederick will use Silicon Kinetics’ three-dimensional, label-free SKi Pro Biomolecular Interaction Analysis Platform in its Protein Chemistry Laboratory to study extracellular binding domains of specific proteins linked to these diseases.
The partnership was struck through the NCI’s Advanced Technology Partnerships Initiative, which is focused on translating research discoveries into treatments for AIDS and cancer patients.
The SKi Pro platform combines nanoporous silicon and optical interferometry to study proteins on 3D biosensor surfaces, Silicon Kinetics said.
The company said that the SKi Pro platform and its SKi Sensor biochips are used to detect protein-protein, protein-drug, or protein-DNA interactions in real time, quantifying binding kinetics, and for other studies of disease pathways and in therapeutic development.
Financial terms of the agreement were not released.